Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered T-Cells take on Hard-to-Treat blood cancers in first human trial

NCT ID NCT06834282

First seen Mar 22, 2026 · Last updated May 24, 2026 · Updated 13 times

Summary

This early-stage study tests a new treatment called CER-1236 for people with certain blood cancers (acute myeloid leukemia, myelodysplastic syndrome, or myelofibrosis) that have not responded to standard therapy. CER-1236 is made from a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals are to check safety and see if the treatment can shrink or eliminate the cancer. About 18 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY ACUTE MYELOID LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Colorado Blood Cancer Institute

    RECRUITING

    Denver, Colorado, 80218, United States

    Contact Email: •••••@•••••

    Contact

  • Sarah Cannon Research Insitute

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact Phone: •••-•••-••••

  • The University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of California, Davis Comprehensive Cancer Center

    NOT_YET_RECRUITING

    Sacramento, California, 95817, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.